Health Care • Biotechnology: Pharmaceutical Preparations
$18.61 ▲ +0.22
(+1.20%)
MKT CAP: $2.37B • VOL: 1.67M
52W L $17 52W H $32
ROARABLE / RQD
D- • 35/100
PIOTROSKI
1 / 9
RCUS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $33.0M | $51.0M | $37.0M |
| YoY Revenue Growth % | -35.3% | +37.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$386.0M | -$330.0M | -$340.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$353.0M | -$283.0M | -$307.0M |
| EBITDA (Normalized) | -$384.4M | -$325.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$482.0M | -$170.0M | -$306.0M |
| Capital Expenditures (CapEx) | $2.0M | $6.0M | — |
| Free Cash Flow (FCF) | -$484.0M | -$176.0M | -$306.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $222.0M | $150.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $631.0M | $485.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RCUS.